Journal of Medicinal Chemistry p. 1 - 6 (1983)
Update date:2022-09-26
Topics:
Lipinski, Christopher A.
A process of bioisosteric drug design is described whereby, in a manner analogous to synthesis, key portions of an effector molecule are successively replaced by pharmacophores or bioisosteres.This process, when applied to histamine, leads to the competitive histamine H2-receptor antagonist prototype 3-amino-5-(2-amino-4-pyridyl)-1,2,4-triazole (7).The biaryl nature of 7 fixes internitrogen distances, and comparison of these with histamine suggests that 7 shares structural features more in common with histamine trans rather than histamine gauche conformations.Alkylation of the prototype pyridylamino group in 7 markedly improves both histamine H2-receptor antagonist and gastric acid antisecretory activity so that the resulting agent, 3-amino-5-<2-(ethylamino)-4-pyridyl>-1,2,4-triazole (8), is more active than cimetidine.
View Morewebsite:http://www.acrospharmatech.com
Contact:+1-3234804688
Address:Flat/RM 1502,Easey Commercial building 253-261 Hennessy Road,Wanchai,HongKong
Xi'an Unique Electronic and Chemical Co., Ltd.
Contact:+86-029-88238008
Address:1703# B BUILDING WEST ELECTRONIC ZONE, XI'AN, CHINA
Contact:+86-0512-69209969
Address:Room 317,Lushan Road,Suzhou New District,Jiangsu Province,China.
Contact:18669908765
Address:Zibo City, Shandong Province, P.R.China
Contact:0833-5590788/5590338/5590055
Address:Victory in the town of Red Star Village,Mount Emei City,industrial concentration area storage processing logistics parkpark
Doi:10.1002/hlca.19820650533
(1982)Doi:10.1080/10426500307867
(2003)Doi:10.1039/d0md00238k
()Doi:10.1007/BF00763631
(1988)Doi:10.1021/jo00184a021
(1984)Doi:10.1002/jps.2600540114
(1965)